




>>Entry Name: Glibenclamide, BAN, INN, JAN

Synonym(s): 5-Chloro-*N*-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxybenzamide, 9Cl. 1-[[*p*-[2-(5-Chloro-*o*-anisamido)ethyl]phenyl]sulfonyl]-3-cyclohexylurea, 8Cl. **Glyburide**, USAN. Calabren. Daonil. DiaBeta. Diabetamide. Euglucon. Gilemal. Glynase. Libanil. Malix. Micronase. Semi-Daonil. Many other names



CAS Registry Number: 10238-21-8

Molecular Formula: C₂₃H₂₈ClN₃O₅S

Molecular Weight: 494.01

Accurate Mass: 493.143819

Percentage Composition: C 55.92%; H 5.71%; Cl 7.18%; N 8.51%; O 16.19%; S 6.49%

Biological Use/Importance: Potassium channel (K_{ATP}) blocker, inhibits drug-induced coronary vasodilation. Antidiabetic

Physical Description: Cryst. (EtOH/DMF) or (MeOH)

Development Status: Marketed drug

Melting Point: Mp 172-174°

Experimental Log P Data: Log P 3.08 (exp)

Calculated Log P Data: Log P 4.08 (calc)

Hazard & Toxicity: LD₅₀ (mus, orl) 3250 mg/kg. Exp. reprod. and teratogenic effects

Aldrich: 37869-0

Sigma: G0639

References:

Aldrich Library of 13C and 1H FT NMR Spectra, 1992, **2**, 1639B, (*nmr*)

Aumüller, W. *et al.*, *Arzneim.-Forsch.*, 1966, **16**, 1640, (*synth*)

Weber, H. *et al.*, *Arzneim.-Forsch.*, 1969, **19**, 1323, (*numerous papers*)

Takla, P.G., *Anal. Profiles Drug Subst.*, 1981, **10**, 337, (*rev*)

Prendergast, B.D., *Clin. Pharm.*, 1984, **3**, 473, (*rev, pharmacol*)

Krall, L.P. *et al.*, *Clin. Ther.*, 1984, **6**, 746, (*rev, pharmacol*)

Negwer, M., *Organic-Chemical Drugs and their Synonyms*, 6th edn., Akademie-Verlag, 1987, 6870, (*synonyms*)

Am. J. Med., Suppl., 1990, **89**, 2A, (*rev*)

Katsuda, Y. *et al.*, *Circulation*, 1995, **92**, 511, (*pharmacol*)

Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 319

Lewis, R.J., *Sax's Dangerous Properties of Industrial Materials*, 8th edn., Van Nostrand Reinhold, 1992, CEH700